ASCELIA

AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY

Ascelia Pharma – Capital Markets Day 2020

Ascelia Pharma company presentation May 2020

Download our fact sheet: Ascelia Pharma factsheet

Lead candidate Mangoral (Phase III) is an MRI imaging drug being developed for detection and localization of liver metastases.

Oncoral (phase II ready) is a novel tablet-based irinotecan formulation, intended for treatment of advanced gastric (stomach) cancer.

• November 5 @ 08:00

  Interim financial report 9M 2020 (Jan-Sep)

• December 3 @ 09:50 - 10:30

  Danske Bank Winter Seminar (virtual event)

• 2021-02-16 @ 08:00

  Full-year financial report 2020 (Jan-Dec)

• 2020-10-21Upgraded estimate of addressable market for Mangoral to $500-600 million annually
• 2020-09-30Invitation to Ascelia Pharma’s virtual Capital Markets Day
• 2020-09-18First commercial scale manufacturing of Mangoral
• 2020-08-20Quarterly Report Q2-2020: First participant in the hepatic study
• 2020-07-31Change in number of shares and votes in Ascelia Pharma AB